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PTMs
AllostericProtein post-translational modiﬁcations (PTMs) are a fast and versatility mechanism used by the cell to
regulate the function of proteins in response to changing conditions. PTMs can alter the activity of pro-
teins by allosteric regulation or by controlling protein interactions, localization and abundance. Recent
advances in proteomics have revealed the extent of regulation by PTMs and the different mechanisms
used in nature to exert control over protein function via PTMs. These developments can serve as the foun-
dation for the rational design of protein regulation. Here we review the advances in methods to deter-
mine the function of PTMs, protein allosteric control and examples of rational design of PTM
regulation. These advances create an opportunity to move synthetic biology forward by making use of
a level of regulation that is of yet unexplored.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The activity and function of proteins is ﬁnely tuned inside the
cell in response to changes in internal and external conditions.
Once a protein is expressed its function can be regulated by inter-
actions with other proteins or with small-molecules. These interac-
tions can cause the protein to be altered in different ways such as
changing its localization or activity. Protein post-translational
modiﬁcations (PTMs) are a common mechanism to regulate pro-
tein function. Examples of well-studied and highly abundant
PTMs include phosphorylation, acetylation and ubiquitylation
(reviewed in Refs. 1,2) that alter the physicochemical properties
of proteins. Each type of PTM is usually associated with a set of
enzymes that can catalyse the addition or removal of the modiﬁca-
tion. For the three above mentioned PTMs these would correspond
to protein kinases and phosphatases, lysine acetylases and
deacetylases and ubiquitin ligases and de-ubiquitylases. PTMs
can also occur without the need of protein enzymes. For example,
it has been shown that acetyl-phosphate (AcP) can acetylate
in vitro many proteins of the Escherichia coli proteome and that
the levels of lysine acetylation in vivo are affected by the metabo-
lism of AcP.3 Regardless of the process that causes the modiﬁca-
tion, PTMs can alter the function of proteins in many different
ways. They are often found in interface regions4 and are knownto tune the binding afﬁnity of protein–protein interactions. The
modiﬁcation of localization signals can reversely regulate protein
localizations5 and in addition PTMs are often able to regulate pro-
tein activities via allosteric regulation.6 For example, the modiﬁca-
tion of protein kinases or chaperones can allosterically control the
activity of these enzymes.7,8
In the past decade, advances in mass-spectrometry and enrich-
ment strategies have increased the capacity to identify PTMs for
different modiﬁcation types.2 In a recent analysis of human pro-
teins, Sharma and colleagues were able to identify over 50,000
phosphosites collected in one experiment.9 Compilation of differ-
ent works have identiﬁed over 200,000 phosphosites, 35,000 acety-
lation sites and 50,000 ubiquitylation sites for human proteins
alone (www.phosphosite.org). These experiments have revealed
the large extent by which the proteome is modiﬁed and how much
PTMs may be modulating protein function. The accumulation of
PTM information for different species has also allowed for the
study of their evolutionary properties.10–13 Perhaps surprisingly,
it was noted that many commonly studied PTM types tend to be
poorly constrained leading some to suggest that a fraction PTM
sites may serve no biological purpose.12 This would be analogous
to the potential lack of function for many transcription-factor bind-
ing events in the genome.14 Given the large number of novel PTMs
discovered and the lack of conservation it has been increasingly
important to develop approaches to study PTM function15–17
(reviewed in Ref. 18). As we systematically characterize the natu-
rally occurring modes of PTM regulation we should be able to
extract rules to use for engineering via rational design.
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work in protein computational modelling (reviewed in Ref. 19).
Protein design approaches use similar computational methods as
used in protein modelling but with the aim of ﬁnding the correct
sequence that would fold into the target structure. There has been
steady progress made in this ﬁeld with successful designs of small
proteins, initially based on naturally occurring folds20,21 and later
also applied to the design of novel folds.22 The same methods have
been used also to engineer protein–protein interactions23,24—re-
viewed in Ref. 25—as well as in enzyme design (reviewed in Ref.
26). We suggest that the large scale characterization of PTM func-
tion in natural systems is opening the door to the rational design of
such regulatory events. Designed PTM regulatory systems could
then be used in higher-order circuits in much the same way that
transcriptional regulatory systems have been put together in syn-
thetic biology to accomplish complex tasks. In this perspective
we review the computational and experimental approaches used
to determine the function of PTMs, the regions in proteins amen-
able for allosteric control as well as some seminal examples of
rational design of PTM regulation.
2. Engineered regulation of interactions, localization and
degradation
2.1. Design of domain–peptide interactions mediated by PTMs
Protein–protein interactions can very often be modulated by
PTMs. The most commonly studied examples are from PTM recog-
nition domains that are also known as ‘reader’ domains for their
capacity to read the modiﬁcation state of a protein. Each PTM type
is often recognized by different protein domain families.27 For
example, the SH2 domain family can recognize tyrosine phospho-
peptides while the 14-3-3 domains bind to serine and threonine
phosphosites. Similarly, Bromo domains recognize acetylation sites
and Ubiquitin binding domains recognize ubiquitin. Like the
enzyme regulators, each particular domain from a domain family
has preferences for speciﬁc residues surrounding the target PTM
site. These can be determined in large scale using different exper-
imental approaches like peptide or protein arrays, phage display
and mass spectrometry (reviewed in Ref. 28). Such studies have
been applied extensively only for a small number of domain fam-
ilies such as the SH2,29 Polo-box,30 malignant brain tumor
(MBT)31 and Bromo domains.32 Such studies deﬁne the sequence
rules that, in part, determine the interaction between these pro-
teins and modiﬁed peptides that exist in the context of full pro-
teins.33 These rules can then be used to design PTM mediated
interactions for desired outcomes. For example, Barnea and col-
leagues designed a receptor tyrosine kinase (RTK) reporter system
using an SH2–phophotyrosine interaction34 (Fig. 1a). In this study
the TEV protease was fused to an SH2 domain that can bind to
auto-phosphorylated RTKs. They then fused a transcription factor
to the cytosolic tail of the RTK with a linker that contained a TEV
cleavage site. In this way, after RTK stimulation and auto-phospho-
rylation the protease gets recruited to the receptor by the phos-
pho-dependent SH2 interaction. The protease cleavage releases
the transcription factor that can elicit a signalling response
(Fig. 1a). A similar strategy has been used to recruit a death effector
domain to activated RTKs and in this way re-direct signalling path-
ways towards the induction of caspase activation and cell death.35
Engineered domain–peptide interactions have also been used to
design kinase sensors36–39 using a general strategy where two dif-
ferent ﬂuorescent domains are joined by an intermediate section
containing a peptide substrate for a kinase of interest a ﬂexible lin-
ker and phospho-binding domain (e.g. SH2 or 14-3-3 domain).
Upon phosphorylation the intra-molecular interaction decreasesthe distance between the ﬂuorescence domains and increases the
efﬁciency of ﬂuorescence resonance energy transfer (FRET).
2.2. Tuning of protein–protein interfaces by PTMs
In addition to regulating interactions through recruitment of
binding domains, PTMs can also tune the binding afﬁnity of protein
interactions by changing the properties of interfaces between glob-
ular domains.4,15 Structural analysis has recently shown that pro-
tein–protein interfaces are enriched for modiﬁcation sites.4,40 In
silico mutagenesis of these regulated interface positions suggests
that many are likely to alter the binding afﬁnity of the interaction.4
In addition, interface phosphosites and acetylation sites show an
above average conservation suggesting that they are more likely
than average sites to be evolutionarily constrained and therefore
functionally important.15 These analyses suggest that PTMs often
tune binding afﬁnity in natural systems. This opens the possibility
of using computational methods to redesign protein interfaces in
order to add PTM regulation.
Computational design of interfaces has been used extensively in
the past (reviewed in Ref. 25). Such efforts have been directed at
improving binding afﬁnity of existing interfaces as well as chang-
ing binding speciﬁcity. For example, Kapp and colleagues have
developed a design strategy to create non-crossreacting (orthogo-
nal) protein–protein interfaces.23 The authors developed this
approach using, as a model interface, the interaction between the
Cdc42 GTPase and Intersection (ITSN) its cognate GTPase exchange
factor (GEF). Copies of these proteins were mutated in order to cre-
ate a Cdc42–ITSN interface that would be functional but would not
cross-react with the original pair. Perhaps the ultimate challenge in
such design efforts is to be able to engineer a novel interface that
does not exist in nature, something that was ﬁrst achieved by
Karanicolas and colleagues using a combination of computational
design and directed evolution.41
The design of PTM regulation of protein interfaces has not yet
been extensively explored. Seminal studies of engineered PTMs
at interfaces come from the structural analysis of small model pep-
tide systems. Szilák and colleagues, for example, used the leucine
zipper coiled coil dimer of a bZIP DNA binding protein to study
the effects of adding a phosphorylation site at different positions
within its sequence (Fig. 1b). They showed that depending on the
position the phosphosite can have both the capacity to destabi-
lize42 or promote43 the association between the dimmer. The addi-
tion of phosphorylable positions was achieved by adding a PKA
kinase recognition motif sequence in the desired positions. In
one of the designs (Fig. 1b, lower diagram), the PKA motif was
introduced such that the phosphosite would establish electrostatic
interactions with two opposite arginines and in this way promote
the dimmer formation. In the second design (Fig. 1b, upper dia-
gram) the introduced phosphosite tends to destabilize the helix
structure and in this way inhibit the formation of the dimmer.
Similar work has been done to engineer a phosphorylation-depen-
dent oligomerization domain based on the Lac repressor oligomer-
ization domain.44 Signarvic and DeGrado engineered a 20-residue
sequence such that 4 unstructured peptides monomers would cre-
ate a four-helical bundle due to phosphorylation by the cyclic
AMP-dependent protein kinase (PKA) (Fig. 1c). Beginning with
the Lac repressor oligomerization domain, a phosphosite was
introduced near the N-terminus leading to a 2–4.6 kcal/mol
increase in the stability of the tetramer (Fig. 1c). More recently,
computational tools were used to design a phosphorylatable PDZ
domain resulting in changes in binding afﬁnity towards a PDZ tar-
get peptide.45 Predictors of PKA substrate recognition were com-
bined with the Rosetta software to scan the Erbin PDZ domains
for positions that would be recognized by PKA without causing a
Figure 1. Design of post-translational regulation of protein–protein interactions. (a) The binding of phosphorylation ‘reader’ domains, like the SH2 domain, to their target
peptides has been well characterized for some proteins. These rules can be used to engineer novel PTM regulated interactions like the recruitment of the TEV protease to an
active RTK. Activation of the receptor causes the phosphorylation of speciﬁc tyrosine residues that recruit the binding of the SH2 domain. The recruited TEV can cleave off a
transcription factor causing a downstream gene-expression response. (b) The leucine zipper pair illustrated here is a model for studying dimerization. Szilák and colleagues
used this model system to study how the introduction of phosphorylation sites at different positions could regulate this protein interaction. The lower-case letters indicate
the positions along the helix. In the example described in the upper diagram the phosphosite was introduced at a position ‘b’ (coloured red) that points way from the interface
but causes a destabilization of the helix (at the positions coloured blue) and therefore inhibit the dimmer formation (arrows). The lower diagram illustrates the addition of a
phosphosite at position ‘e’ (coloured yellow) pointing towards the interface where the phosphosite can interact with two opposing arginines (coloured magenta) and stabilize
the interaction. (c) The Lac repressor oligomerization domain is another model system used to study protein–protein interactions. Signarvic and DeGrado found that
phosphosites introduced in the monomer towards the N-terminus, illustrated here, caused an increase in the stability of the tetramer. (d) The structure of a Erbin PDZ (PDB:
1MFG) bound to a target peptide is shown. The positions highlighted were selected for the introduction of an engineered target site for the PKA kinase. The corresponding
mutations needed to create a PKA target site are shown in the sequences above the structure.
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experimentally (Fig. 1d) with some resulting in changes in binding
afﬁnity and/or speciﬁcity.
2.3. Design of tunable protein localization and degradation
Protein localization and degradation are often also controlled by
PTMs. Degradation in particular is often determined by ubiquityla-
tion. Protein ubiquitylation in turn can be controlled by phosphory-
lation by what is commonly known as phospho-degron motifs.46–48
The phosphorylation of speciﬁc peptide sequences can result in the
recruitment of ubiquitin ligases that have phospho-binding domains
causing the ubiquitylation of nearby lysines. A few examples of
phospho-dependent ubiquitylation events have been studied in
detail to determine the rules required for the creation of a phos-
pho-degron. These sequence motifs can in principle be grafted ontoany protein of interest causing the degradation rate of target protein
to depend on a kinase activity. A similar approach could be used to
engineered tunable localization by grafting localization sequence
motifs that are controlled by PTMs.5 Grafting of tunable localization
signals has been achieved already for nuclear localization signals
that are controlled by small molecules49,50 or light.51,52 Once devel-
oped, these PTM dependent degradation or localization signals could
serve as highly modular tags and used to build higher order biolog-
ical ‘circuits’ as it has been done extensively in synthetic biology.53
3. Engineering protein allosteric control
3.1. Natural examples of allosteric regulation
Allosteric regulation is deﬁned by the binding of another mole-
cule or the PTM regulation of a region that is distinct from the
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allosteric mechanisms was the ﬁrst mode of regulation by PTMs
to be studied. Krebs and Fischer ﬁrst discovered that the conver-
sion between different states of glycogen phosphorylase was con-
trolled by phosphorylation.54 Posterior structural work showed
that the phosphorylation of a single residue (S14) results in a large
change in the N-terminal region that changes the mode of binding
of the dimer and subsequent enzyme activation.55 Since these sem-
inal studies other proteins have been shown to be allosterically
regulated by PTMs. For example, the spindle checkpoint protein
Mad2 was shown to undergo a conformation transition that was
dependent on the phosphorylation of S19556 (Fig. 2a).The c-termi-
nal tail of Mad2 can be in two conformations, either exposing
(open) or burying (closed) the c-terminal tail inside the protein.
Phospho-S195 would be unfavourable in the closed conformation
since it would place a negative charge inside the hydrophobic core
of the protein. Kim and colleagues showed that the mutation
S195D mimicked the phosphorylation of S195 and prevented the
conformation transitions of Mad2, locking it in an open state.56
Single phosphorylation sites can cause extensive changes inFigure 2. Allosteric regulation by post-translational modiﬁcations. (a) The structures of th
spindle checkpoint protein Mad2 are shown. The phosphorylation of serine 195 promote
similar conformation. Sections in green indicate the regions showing the highest c
conformations. (b) The RING ubiquitin ligase c-Cbl contains 3 globular domains connect
conformations that are regulated by protein phosphorylation. In the unphosphorylated
PDB: 1FBV). After phosphorylation LH and RING domain change their orientation relative
(PDB: 4A4C). This changes the orientation and distance between the E2 and the target
(purple, PDB: 4IF4) conformations of the two-component response regulator VraR. Beryllo
b-hairpin used to study the consequence of phosphorylation on allosteric regulation
phosphosites and the impact on hairpin formation was evaluated. (e) and (f) The EF-han
sensor by introducing the phosphorylation sites highlighted green in the sequences. Ev
structure.protein conformation as seen in the regulation of the RING ubiqui-
tin ligase c-Cbl57 (Fig. 2b). Like other Cbl proteins, c-Cbl contains a
RING domain, an LHR domain and TKBD domain (Fig. 2b, upper
diagram). The TKBD domain determines substrate speciﬁcity while
the LHR and RING domains are important for the binding to E2 and
catalysing the ubiquitylation of target substrates. c-Clb was shown
to be regulated by phosphorylation in Y371 and detailed structural
studies by Dou and colleagues have demonstrated that this is
achieved via allosteric regulation. In the absence of the phospho-
site c-Clb adopts a closed and auto-inhibit conformation where
the RING domain interacts with the TKBD domain in way that inhi-
bits the interaction between the E2 and the target protein (Fig. 2b).
Phosphorylation of Y371 is not compatible with the closed confor-
mation and abolishes the auto-inhibition of c-Clb.57 The open con-
formation results in a large rotation of the RING domain relative to
the rest of the c-Clb protein bringing the E2 closer to the target
protein (Fig. 2b). Understanding the allosteric regulation and con-
formation variability of proteins could be important for therapeu-
tic purposes. For example, methicillin-resistant Staphylococcus
aureus (MSRA) were found to be sensitive to deletion of the twoe open (O-Mad2, PDB: 1DUJ) and closed (C-Mad2, (PDB: 1S2H) conformations of the
s the open conformation. The protein segments coloured in yellow show an overall
hange in conformation. The N-terminal region is highlighted in purple in both
ed by linkers illustrated in the upper diagram. This protein can adopt two different
form the LH domain packs against the RING and TKBD domain (opaque structures,
to the TKBD domain drastically towards the binding interface of the target protein
protein. (c) The unphosphorylated (yellow, PDB: 4GVP) and berylloﬂuoride-actived
ﬂuoride (BeF3) is mimicking phosphorylation. (d) Structure of a 12 residue peptide
. The second position (X in the ﬁgure) of the hairpin was changed to different
d helix-loop-helix structure was used to design a serine (e) and tyrosine (f) kinase
olutionary conserved glutamate at position 12 is highlighted in the sequences and
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system composed of a regulator (VraS) that can act as a kinase or
phosphatase for the transcription factor response partner VraR.
Phosphorylation of VraR increases its transcriptional activity by
an allosteric mechanism (Fig. 2c).59 Leonard and colleagues have
shown that berylloﬂouride (BeF3), acting as a phosphorylation
mimic, opens the conformation of VraR (Fig. 2c) allowing for its
dimerization and activation. Understanding the allosteric regula-
tion of VraR by phosphorylation allows for the exploration of addi-
tional therapeutic strategies against MSRA.
3.2. Computational approaches to study allosteric regulation
The computational design of allosteric regulation requires a
capacity to predict how a perturbation to one part of a protein,
by a PTM or interaction, might result in a conformation change
with impact on protein activity. One of the computational
approaches used to study allosteric regulation is Molecular
Dynamics (MD) that tries to simulate conformational changes over
long timescales in protein structures. MD may often aid in the
interpretation of existing structural information. For example,
Espinoza-Fonseca and colleagues used MD to study the phospho-
regulation of the N-terminal region of the regulatory light chain
(RLC) of muscle myosin.60 This region is unstructured and to fur-
ther study the dynamics of this regions MD simulations of the
S19 phosphorylated and unphosphorylated suggested a phospho-
rylation induced disorder-to-order transition that was in-line with
previous experimental data.61 The MD simulations provide the
additional insight of producing atomic models of the potential dif-
ferent conformational states. Changes in conformation due to PTMs
may also be important for drug interactions and drug design. This
has been illustrated with the study of protonation driven changes
in conformation of cathepsin B.62 Similar to PTMs, protonation sta-
tus, due to change in pH, may alter the overall dynamics of the
whole enzyme. Cathepsin B is inactivated in alkaline pH causing
allosteric protection to the inhibitor heparin.63 Different pH condi-
tions where simulated by Costa and colleagues and these simula-
tions supported the hypothesis that the heparin binding to an
allosteric site could stabilize the more stable conformation.62
These studies help to understand the mechanism activation of
catB which might help in designing new catB inhibitors.
Other structure based computational approaches have been
used to more directly attempt to identify allosteric ‘pathways’ or
networks of residues that are important to communicate the infor-
mation of a binding event or PTM. For example, Mitternach and
Berezovky used Calpha elastic networks and normal mode analysis
to identify potential protein motions and then used these to study
the allosteric regulation by ligand binding or PTMs.64 An alterna-
tive approach was used by Cilia and colleagues whereby the con-
formation of side-chains across an NMR ensemble was probed
using a rotomer library and the FoldX force ﬁeld. These samples
were then analysed to identify clusters of coupled side-chain that
could predict residues involved in the long-range communication
of the binding event for a PDZ domain.65
A sequence based computational approach that is commonly
used to study allosteric regulation is protein sequence co-evolu-
tion. One of the more popular and successful of these algorithms
for prediction of allosteric communication within proteins is the
statistical coupling analysis (SCA).66 SCA measures the covariation
between pairs of amino acids in large multiple sequence protein
alignment of a given protein family. The sequence alignment con-
tains the long-term evolutionary record of a protein family and SCA
assumes that functionally relevant coupling between amino acids
should drive co-evolution of those residues. Groups of contiguous
co-evolving residues form networks or ‘sectors’ which are spatially
organized within the protein and they can be linked to manysurface sites distributed throughout the structure.67 These surface
linked co-evolving sectors have been proposed as potential allos-
teric sites.68,69 This approach has been used to study allosteric reg-
ulation in natural systems and although this has not yet been used
to engineer PTM control it has been used to design a peptide bind-
ing domain70 and to guide allosteric drug design.71 Novinec and
colleagues reported the discovery of a low-molecular-weight allos-
teric inhibitor of the collagenolytic cystein peptidase cathepsin K
using SCA. In this study, the authors ﬁrst predicted surface sites
in the peptidase that are likely to be connected to the active site
via networks of co-evolving sites. They then used high-throughput
docking of compound libraries to these surface sites to ﬁnd poten-
tial allosteric regulators.
3.3. Examples of engineered allosteric control by
phosphorylation
The computational methods described above have yet not been
applied to design PTM allosteric regulation. However, some
authors have used short peptide systems to study the conse-
quences of PTM regulation on protein conformation and in this
way design PTM conformational switches. For example, Riemen
and Waters analysed a 12 residue peptide designed to fold into a
b-hairpin structure where the properties that determine the struc-
ture are well understood.72,73 In one of the studies the second posi-
tion of the hairpin was exchanged between a serine and different
phosphosites (Fig. 2d). The introduction of any phosphosite at posi-
tion 2 tended to destabilize the hairpin formation.72 A similar pep-
tide system was also used to test the combination of
phosphorylation and methylation on the stability of the b-hairpin
structure.73 Another elegant example of controlled conformational
switches was achieved by Balakrishnan and Zondlo making use of
the EF-hand domain.74 The EF hand domain contains a calcium-
binding motif that binds a metal atom, for example calcium in
Calmodulin. However, due to similar electronics and ionic radii,
EF-hands can also bind lanthanides, endowing these domains with
luminescent properties that can be used as reporter systems. The
authors engineered a protein kinase recognition sequence into an
EF-hand and used luminescent as a readout for the folding of the
domain. The EF-hand sequence is robust to mutations in different
positions; however residue 12 that binds the metal ion in bidentate
manner is invariantly Glutamic acid (Fig. 2e, EF Hand and struc-
ture). Binding of the ion to the EF-hand changes its conformation
into a well-folded helix-loop-helix structure due to ﬁve side chain
groups and one main chain carbonyl. The engineered EF-hand was
built by modiﬁcation of Glu in 12 position to phosphoserine
creating motifs that are recognized by kinases (Fig. 2e, pKID-pKA,
pKID-pPKC and pKID-ERK). The created domains act as a phospho-
rylation dependent switch that folds only when phosphorylated in
position 12. A similar strategy was used to engineer an EF-hand
that would fold after tyrosine phosphorylation.75 The authors
reasoned that phosphotyrosine on the 11th position in EF-hand
motif can replicate Glu in the 12th position given the large size of
the tyrosine side-chain (Fig. 2f). These phosphorylation dependent
EF-hands should be compatible with different kinase speciﬁcity
preferences and might serve as modules to create allosteric regula-
tion in other proteins by grafting them in appropriate locations.
4. Summary
The engineering of gene-expression regulatory circuits has
already a long tradition (reviewed in Ref. 76). An increasing under-
standing of the design principles underlying natural systems and a
well characterized list of components have allowed researchers to
build circuits that achieve complex tasks (reviewed in Ref. 77). The
design of biological circuits may one day allow for cell-based
2882 M. Strumillo, P. Beltrao / Bioorg. Med. Chem. 23 (2015) 2877–2882therapeutics that are not easily achieved with current conventional
approaches.78 However, the engineering of post-translational con-
trol is currently lagging behind when compared to transcriptional
regulation. Recent progress in proteomics is revealing the extent
by which natural proteins are regulated by PTMs and in turn this
is driving a renewed interest in approaches to determine the mech-
anisms by which different types of PTM exert their control. Here
we have reviewed examples of the different modes of regulation
by PTMs in natural systems, seminal works on the engineering of
PTM regulation as well as computational tools that can be used
for the computational design of PTM regulation. We think that
the time is ripe for the development of parts and circuits based
on PTM control. This will allow synthetic biology efforts to add reg-
ulation that can occur at faster time scales and through a much
wider range of mechanisms.
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